Wilmington Savings Fund Society FSB Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Wilmington Savings Fund Society FSB boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 278.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,660 shares of the biopharmaceutical company's stock after buying an additional 13,729 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in Gilead Sciences were worth $1,564,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. increased its stake in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 238 shares during the last quarter. nVerses Capital LLC acquired a new stake in Gilead Sciences during the third quarter worth about $25,000. Valued Wealth Advisors LLC raised its stake in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 161 shares during the period. Cedar Wealth Management LLC grew its stake in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 164,211 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 447,234 shares of company stock valued at $41,288,086. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

GILD traded up $0.24 on Friday, reaching $91.86. The company had a trading volume of 7,515,462 shares, compared to its average volume of 7,068,425. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company's fifty day moving average is $89.96 and its 200 day moving average is $79.55. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The stock has a market cap of $114.48 billion, a P/E ratio of 1,020.61, a P/E/G ratio of 2.38 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.35%. Gilead Sciences's payout ratio is presently 3,422.22%.

Analysts Set New Price Targets

A number of brokerages have weighed in on GILD. Cantor Fitzgerald reiterated a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday. Maxim Group downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Citigroup began coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Bank of America reaffirmed a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, Robert W. Baird raised their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $96.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.